Summit starts phase 3 trial of ivonescimab in lung cancer

Summit Therapeutics (NASDAQ: SMMT) launched a Phase III trial (HARMONi-10) for ivonescimab in lung cancer, comparing it to durvalumab. The trial aims to evaluate progression-free survival as the primary endpoint, with global site activations expected in Q4 2026. Ivonescimab, a PD-1 x VEGF bispecific antibody, is not approved in the U.S. or Europe but has marketing authorization in China. Over 5,000 patients have been treated in clinical studies globally, and over 100,000 in China.

Original reporting
Published Nov 18, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$SMMT
Neutral
high confidence
Mentioned
$SMMT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SMMTNeutralMed
01

Why it matters

The Phase III start is the first public indication of a new pivotal study, providing a fresh catalyst for the stock. Investors will watch for enrollment speed and early safety signals.

02

Market read

The announcement adds a new near‑term catalyst for Summit Therapeutics, with potential spill‑over to other oncology biotech stocks.

03

What to watch

The drug already has Chinese approval; success in the U.S. could unlock a large new market beyond current revenues.

Relevance 8/10Novelty 8/10Timing: later this year (Q4 2026 trial start)

Background

Summit Therapeutics (NASDAQ:SMMT) is a clinical‑stage biotech focused on bispecific antibodies. Ivonescimab is already approved in China and is being evaluated against the current standard durvalumab in the U.S. and Europe.

Company-level read

Ticker impact

$SMMTNeutralHigh confidence
Context

Summit Therapeutics announced the initiation of the global Phase III HARMONi-10 trial for ivonescimab in Stage III non‑small cell lung cancer.

Expected impact

potential modest upside as investors price in trial progress, with downside risk if early data are negative

Evidence & confidence

Phase III initiation is a material development for a biotech; market typically reacts to trial milestones, but the impact will unfold over months.

Market effects

Adds to the pipeline momentum in the oncology biotech sector, potentially lifting peers developing PD‑1/VEGF bispecifics.

Limited to U.S. and European biotech markets; no immediate macro effect.

Modest, as the trial is global but impact is confined to biotech investors.

Counterpoint

If the market has already priced in optimism, a neutral or negative trial read could trigger a sell‑off.

Key entities

  • Summit Therapeutics Inc.

    Biotech developer of ivonescimab, listed on NASDAQ under SMMT.

  • Akeso Inc.

    Chinese partner that commercializes ivonescimab in China (HKEX:9926.HK).

Related articles

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$SMMTMed

Summit Therapeutics Plans Global Phase III HARMONi-10 Trial of Ivonescimab

Summit Therapeutics (SMMT) plans a global Phase III trial (HARMONi-10) for ivonescimab vs. durvalumab in treating unresectable Stage III non-small cell lung cancer. The trial, set to begin in Q4 2026, aims to study patients without disease progression after initial treatment, with progression-free survival as the primary endpoint. This is Summit's sixth Phase III ivonescimab study and fourth in this cancer type, according to the company.

$SMMTMed

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung…

Summit Therapeutics Inc. (SMMT) filed an SEC Form 8-K — Other Events. Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Global Registration-Enabling Study to Evaluate Ivonescimab Versus Durvalumab as Consolidation Therapy Following Concurre